Table 1 Patient characteristics
MTV and TLG measured | PET-0 not done or not measurable | ||
|---|---|---|---|
N = 107 | N = 1032 | ||
Age | Median (range) | 36 (18–75) | 38 (18–75) |
Sex | Female | 44 (41%) | 441 (43%) |
Male | 63 (59%) | 591 (57%) | |
Country | Germany | 82 (77%) | 935 (91%) |
Switzerland | 13 (12%) | 49 (5%) | |
Austria | 7 (7%) | 34 (3%) | |
Netherlands | 5 (5%) | 14 (1%) | |
Performance status | ECOG = 0 | 100 (94%) | 948 (92%) |
ECOG = 1 | 7 (6%) | 82 (8%) | |
ECOG = 2 | - | 1 (< 1%) | |
Ann Arbor stage | IA | 31 (29%) | 278 (27%) |
IB | 4 (4%) | 42 (4%) | |
IIA | 69 (65%) | 656 (64%) | |
IIB | 3 (3%) | 56 (5%) | |
Treatment group | Standard CMT | 59 (55%) | 514 (50%) |
PET-stratified | 48 (45%) | 518 (50%) | |
PET-2 result | DS1 | 49 (46%) | 463/932 (50%) |
DS2 | 13 (12%) | 159/932 (17%) | |
DS3 | 29 (27%) | 199/932 (21%) | |
DS4 | 16 (15%) | 111/932 (12%) | |
Failure in terms of PFS | No | 99 (93%) | 943 (91%) |
Yes | 8 (7%) | 89 (9%) |